7 results on '"Michelle Gilmor"'
Search Results
2. RGX-121 gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in human study
- Author
-
Paul Harmatz, Can H. Ficicioglu, Roberto Giugliani, Deepa Rajan, Joseph Hagood, Michele Fiscella, Lin Yang, Michelle Gilmor, Yoonjin Cho, Dawn Phillips, and Paulo Falabella
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,Genetics ,Molecular Biology ,Biochemistry - Published
- 2023
- Full Text
- View/download PDF
3. Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain
- Author
-
Stanley Fahn, Michelle Gilmor, Pauline Carter, Barbara Hubbard, David Alexoff, Payton King, Lisa Muench, Colleen Shea, Karen Apelskog-Torres, Elena Shumay, Millard Jayne, Fred McCall-Perez, Jean Logan, Frank Telang, Gene-Jack Wang, Nora D. Volkow, Joanna S. Fowler, and Youwen Xu
- Subjects
Adult ,Male ,Clorgyline ,Monoamine Oxidase Inhibitors ,Adolescent ,Monoamine oxidase ,Administration, Oral ,Pharmacology ,Administration, Cutaneous ,03 medical and health sciences ,First pass effect ,Young Adult ,0302 clinical medicine ,Cocaine ,Selegiline ,medicine ,Humans ,Carbon Radioisotopes ,Amphetamine ,Monoamine Oxidase ,030304 developmental biology ,Dopamine transporter ,0303 health sciences ,Dopamine Plasma Membrane Transport Proteins ,biology ,Dose-Response Relationship, Drug ,business.industry ,Functional Neuroimaging ,Brain ,3. Good health ,Psychiatry and Mental health ,Positron-Emission Tomography ,biology.protein ,Zydis ,Original Article ,Monoamine oxidase B ,Monoamine oxidase A ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10 mg/day oral) that is used in the treatment of Parkinson's disease. However, controlled studies have demonstrated antidepressant activity for high doses of oral selegiline and for transdermal selegiline suggesting that when plasma levels of selegiline are elevated, brain MAO-A might also be inhibited. Zydis selegiline (Zelapar) is an orally disintegrating formulation of selegiline, which is absorbed through the buccal mucosa producing higher plasma levels of selegiline and reduced amphetamine metabolites compared with equal doses of conventional selegiline. Although there is indirect evidence that Zydis selegiline at high doses loses its selectivity for MAO-B, there is no direct evidence that it also inhibits brain MAO-A in humans. We measured brain MAO-A in 18 healthy men after a 28-day treatment with Zydis selegiline (2.5, 5.0, or 10 mg/day) and in 3 subjects receiving the selegiline transdermal system (Emsam patch, 6 mg/day) using positron emission tomography and the MAO-A radiotracer [(11)C]clorgyline. We also measured dopamine transporter (DAT) availability in three subjects from the 10 mg group. The 10 mg Zydis selegiline dose significantly inhibited MAO-A (36.9±19.7%, range 11-70%, p0.007)) but not DAT; and while Emsam also inhibited MAO-A (33.2±28.9 (range 9-68%) the difference did not reach significance (p=0.10)) presumably because of the small sample size. Our results provide the first direct evidence of brain MAO-A inhibition in humans by formulations of selegiline, which are currently postulated but not verified to target brain MAO-A in addition to MAO-B.
- Published
- 2014
4. First Nations Peoples’ Participation in the Development of Population-Wide Food and Nutrition Policy in Australia: A Political Economy and Cultural Safety Analysis
- Author
-
Jennifer Browne, Michelle Gilmore, Mark Lock, and Kathryn Backholer
- Subjects
indigenous health ,aboriginal organisations ,cultural safety ,food policy ,nutrition policy ,political economy ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundHealthy and sustainable food systems underpin the well-being of Indigenous peoples. Increasingly governments are taking action to improve diets via population-wide policies. The United Nations Declaration on the Rights of Indigenous People states that Indigenous peoples have the right to participate in all decisions that affect them. We analysed Australian national food and nutrition policy processes to determine: (i) the participation of Aboriginal organisations, (ii) the issues raised in Aboriginal organisations’ policy submissions, and (iii) the extent to which Aboriginal organisations’ recommendations were addressed in final policy documents. MethodsPolitical economy and cultural safety lenses informed the study design. We analysed publicly-available documents for Australian population-wide food and nutrition policy consultations occurring 2008-2018. Data sources were policy documents, committee reports, terms of reference and consultation submissions. The submissions made by Aboriginal organisations were thematically analysed and key policy recommendations extracted. We examined the extent to which key recommendations made by Aboriginal organisations were included in the subsequent policy documents. ResultsFive food and nutrition policy processes received submissions from Aboriginal organisations. Key themes centred on self-determination, culturally-appropriate approaches to health, and the need to address food insecurity and social determinants of health. These messages were underrepresented in final policy documents, and Aboriginal people were not included in any committees overseeing policy development processes. ConclusionThis analysis suggests that very few Aboriginal organisations have participated in Australian population-wide food and nutrition policy processes and that these policy development processes are culturally unsafe. In order to operationalise First Nations peoples’ right to self-determination, alternative mechanisms are required to redress the power imbalances preventing the full participation of Aboriginal and Torres Strait Islander peoples in population-wide food and nutrition policy decisions. This means reflecting on deeply embedded institutional structures and the normative assumptions upon which they rest.
- Published
- 2021
- Full Text
- View/download PDF
5. Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour
- Author
-
Chad M. VanDenBerg, Lawrence F. Blob, Bryan J. Campbell, Eva M. Kemper, Albert J. Azzaro, Melvin Sharoky, and Michelle Gilmor Gilmor
- Subjects
Adult ,Male ,Monoamine Oxidase Inhibitors ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,Monoamine oxidase ,Tyramine ,Blood Pressure ,Placebo ,Administration, Cutaneous ,chemistry.chemical_compound ,Pharmacokinetics ,Double-Blind Method ,Cheese ,Selegiline ,medicine ,Ingestion ,Humans ,Drug Interactions ,business.industry ,Middle Aged ,Psychiatry and Mental health ,Blood pressure ,chemistry ,Anesthesia ,Antidepressant ,Neurology (clinical) ,business ,medicine.drug - Abstract
Background:Monoamine oxidase inhibitors are well recognized as effective antidepressant agents but are rarely used due, in part, to the risk of hypertensive crisis following the ingestion of foods high in tyramine (“cheese reaction”). A selegiline transdermal system (STS) was developed to provide antidepressant concentrations of selegiline in the brain, while preserving the gastrointestinal monoamine oxidase A (MAO-A) barrier. The present study was conducted to determine the effect of the STS 6 mg/24 hour on cardiovascular safety following the ingestion of ∼400 mg of tyramine consumed as a component of aged cheeses.Methods:In this open-label, single-center phase I study, cardiovascular vital signs were recorded following tyramine challenges during placebo and STS 6 mg/24 hr treatment. Subjects were observed for clinical signs and symptoms of a pressor response and/or potential hypertensive crisis during and following the challenges.Results:Ingestion of tyramine-enriched meals following 13 consecutive days of treatment with the STS 6 mg/24 hr (pharmacokinetic steady-state) produced no clinically significant changes in cardiovascular vital signs in 12 healthy adult male subjects. No evidence of a tyramine pressor effect on systolic blood pressure or evidence of hypertensive crisis occurred during the STS treatment.Conclusion:These results suggest that STS 6 mg/24 hr may be administered without concern for dietary tyramine consumption.
- Published
- 2006
6. Changing medical students’ attitudes to and knowledge of deafness: a mixed methods study
- Author
-
Michelle Gilmore, Anna Sturgeon, Clare Thomson, David Bell, Sophie Ryan, James Bailey, Kieran McGlade, and Jayne V. Woodside
- Subjects
Deaf awareness ,Deafness ,Attitudes ,Knowledge ,Medical students ,Special aspects of education ,LC8-6691 ,Medicine - Abstract
Abstract Background and aim Communication with healthcare professionals is challenging for those with hearing loss. This study aimed to determine the impact dedicated deaf awareness training could have on medical student’s attitudes to and knowledge of deafness, and to explore ways of incorporating deaf awareness training into the core undergraduate medical curriculum. Methods A validated questionnaire was used to measure attitudes to and knowledge of deafness in those taking an optional deaf awareness and basic sign language module for second year medical students compared to students who took another module. Previous students on this module were also contacted and asked to complete the same questionnaire. Focus groups with these students explored ways to incorporate deaf awareness training into the core undergraduate medical curriculum. Results After completing the module, students had a more positive attitude to deaf individuals (p
- Published
- 2019
- Full Text
- View/download PDF
7. Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.
- Author
-
Blob LF, Sharoky M, Campbell BJ, Kemper EM, Gilmor MG, VanDenberg CM, and Azzaro AJ
- Subjects
- Administration, Cutaneous, Adolescent, Adult, Double-Blind Method, Drug Interactions, Drug-Related Side Effects and Adverse Reactions, Humans, Male, Middle Aged, Monoamine Oxidase Inhibitors administration & dosage, Selegiline administration & dosage, Blood Pressure drug effects, Cheese, Monoamine Oxidase Inhibitors pharmacology, Selegiline pharmacology, Tyramine pharmacology
- Abstract
Background: Monoamine oxidase inhibitors are well recognized as effective antidepressant agents but are rarely used due, in part, to the risk of hypertensive crisis following the ingestion of foods high in tyramine ("cheese reaction"). A selegiline transdermal system (STS) was developed to provide antidepressant concentrations of selegiline in the brain, while preserving the gastrointestinal monoamine oxidase A (MAO-A) barrier. The present study was conducted to determine the effect of the STS 6 mg/24 hour on cardiovascular safety following the ingestion of approximately 400 mg of tyramine consumed as a component of aged cheeses., Methods: In this open-label, single-center phase I study, cardiovascular vital signs were recorded following tyramine challenges during placebo and STS 6 mg/24 hr treatment. Subjects were observed for clinical signs and symptoms of a pressor response and/or potential hypertensive crisis during and following the challenges., Results: Ingestion of tyramine-enriched meals following 13 consecutive days of treatment with the STS 6 mg/24 hr (pharmacokinetic steady-state) produced no clinically significant changes in cardiovascular vital signs in 12 healthy adult male subjects. No evidence of a tyramine pressor effect on systolic blood pressure or evidence of hypertensive crisis occurred during the STS treatment., Conclusion: These results suggest that STS 6 mg/24 hr may be administered without concern for dietary tyramine consumption.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.